Table 1.

Summary of studies ^a included in this pooled analysis

Study number	Dates, locations	Study medicationb	Patients (n) by study
Study 1 (D1050196) 17	May 2004–Dec 2004,	Lurasidone 80 mg/d	86
Phase II	22 U.S. sites	Placebo	83
Study 2 (D1050229) 18	Oct 2007–Dec 2008,	Lurasidone 40 mg/d	120
Phase III	multinational,	Lurasidone 80 mg/d	116
	48 sites (21 U.S. sites)	Lurasidone 120 mg/d	123
		Placebo	122
Study 3 (D1050231) 19	Jan 2008–June 2009,	Lurasidone 40 mg/d	116
Phase III	multinational,	Lurasidone 120 mg/d	109
	52 sites (25 U.S. sites)	Placebo	111
		Olanzapine 15 mg/dc	119
Study 4 (D1050233) 20	Oct 2008–June 2010,	Lurasidone 80 mg/d	116
Phase III	multinational,	Lurasidone 160 mg/d	112
	63 sites (24 U.S. sites)	Placebo	116
		Quetiapine XR 600 mg/dc	110

^aAll were 6-week, randomized, placebo-controlled, parallel-group, fixed-dose studies.

^bStudy medication was administered in the morning with food in Studies 1-3, and in the evening with food in Study 4.

^cIncluded in the individual study to confirm assay sensitivity, but not included in this pooled analysis.